Abstract
The clinical benefit and steroid-sparing effect of treatment with the anti-immunoglobulin-E (IgE) antibody, omalizumab, was assessed in patients with moderate-to-severe allergic asthma. After a run-in period, 546 allergic asthmatics (aged 12-76 yrs), symptomatic despite inhaled corticosteroids (500-1,200 μg daily of beclomethasone dipropionate), were randomized to receive double-blind either placebo or omalizumab every 2 or 4 weeks (depending on body weight and serum total IgE) subcutaneously for 7 months. A constant beclomethasone dose was maintained during a 16-week stable-steroid phase and progressively reduced to the lowest dose required for asthma control over the following 8 weeks. The latter dose was maintained for the next 4 weeks. Asthma exacerbations represented the primary variable. Compared to the placebo group, the omalizumab group showed 58% fewer exacerbations per patient during the stable-steroid phase (p
| Original language | English |
|---|---|
| Pages (from-to) | 254-261 |
| Number of pages | 8 |
| Journal | European Respiratory Journal |
| Volume | 18 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2001 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pulmonary and Respiratory Medicine
Cite this
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. / Solèr, M.; Matz, J.; Townley, R.; Buhl, R.; O'Brien, J.; Fox, H.; Thirlwell, J.; Gupta, N.; Della Cioppa, G.
In: European Respiratory Journal, Vol. 18, No. 2, 2001, p. 254-261.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
AU - Solèr, M.
AU - Matz, J.
AU - Townley, R.
AU - Buhl, R.
AU - O'Brien, J.
AU - Fox, H.
AU - Thirlwell, J.
AU - Gupta, N.
AU - Della Cioppa, G.
PY - 2001
Y1 - 2001
N2 - The clinical benefit and steroid-sparing effect of treatment with the anti-immunoglobulin-E (IgE) antibody, omalizumab, was assessed in patients with moderate-to-severe allergic asthma. After a run-in period, 546 allergic asthmatics (aged 12-76 yrs), symptomatic despite inhaled corticosteroids (500-1,200 μg daily of beclomethasone dipropionate), were randomized to receive double-blind either placebo or omalizumab every 2 or 4 weeks (depending on body weight and serum total IgE) subcutaneously for 7 months. A constant beclomethasone dose was maintained during a 16-week stable-steroid phase and progressively reduced to the lowest dose required for asthma control over the following 8 weeks. The latter dose was maintained for the next 4 weeks. Asthma exacerbations represented the primary variable. Compared to the placebo group, the omalizumab group showed 58% fewer exacerbations per patient during the stable-steroid phase (p
AB - The clinical benefit and steroid-sparing effect of treatment with the anti-immunoglobulin-E (IgE) antibody, omalizumab, was assessed in patients with moderate-to-severe allergic asthma. After a run-in period, 546 allergic asthmatics (aged 12-76 yrs), symptomatic despite inhaled corticosteroids (500-1,200 μg daily of beclomethasone dipropionate), were randomized to receive double-blind either placebo or omalizumab every 2 or 4 weeks (depending on body weight and serum total IgE) subcutaneously for 7 months. A constant beclomethasone dose was maintained during a 16-week stable-steroid phase and progressively reduced to the lowest dose required for asthma control over the following 8 weeks. The latter dose was maintained for the next 4 weeks. Asthma exacerbations represented the primary variable. Compared to the placebo group, the omalizumab group showed 58% fewer exacerbations per patient during the stable-steroid phase (p
UR - http://www.scopus.com/inward/record.url?scp=0034881877&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034881877&partnerID=8YFLogxK
U2 - 10.1183/09031936.01.00092101
DO - 10.1183/09031936.01.00092101
M3 - Article
VL - 18
SP - 254
EP - 261
JO - European Respiratory Journal
JF - European Respiratory Journal
SN - 0903-1936
IS - 2
ER -